Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 254 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Idiopathic Pulmonary Fibrosis - Overview 10
Idiopathic Pulmonary Fibrosis - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 18
Products under Development by Companies 19
Products under Development by Universities/Institutes 24
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 25
Assessment by Target 25
Assessment by Mechanism of Action 29
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 37
AdAlta Ltd 37
Aeolus Pharmaceuticals Inc 37
Allinky Biopharma 38
apceth Biopharma GmbH 38
Apellis Pharmaceuticals Inc 39
Asahi Kasei Pharma Corp 39
aTyr Pharma Inc 40
Biogen Inc 40
Bioneer Corp 41
BLR Bio LLC 41
Bristol-Myers Squibb Company 42
Celgene Corp 42
Celldex Therapeutics Inc 43
Chiesi Farmaceutici SpA 43
Compugen Ltd 44
Cynata Therapeutics Ltd 44
F. Hoffmann-La Roche Ltd 45
FibroGen Inc 45
FibroStatin SL 46
Galapagos NV 46
GenKyoTex SA 47
GlaxoSmithKline Plc 47
Glenmark Pharmaceuticals Ltd 48
Global Blood Therapeutics Inc 48
GNI Group Ltd 49
Histocell SL 49
iBio Inc 50
Inventiva 50
Isarna Therapeutics GmbH 51
Kadmon Corp LLC 51
Kasiak Research Pvt Ltd 52
Kyorin Pharmaceutical Co Ltd 52
Lung Therapeutics Inc 53
Merck & Co Inc 53
miRagen Therapeutics Inc 54
MorphoSys AG 54
Nuevolution AB 55
Pharmaxis Ltd 55
Promedior Inc 56
ProMetic Life Sciences Inc 56
Pulmatrix Inc 57
Re-Pharm Ltd 57
Redx Pharma Plc 58
Respira Therapeutics Inc 58
Ribomic Inc 59
Saje Pharma LLC 59
Samumed LLC 59
Sanofi 60
Sorrento Therapeutics Inc 60
SPR Biosciences LLC 61
Therabron Therapeutics Inc 61
Unity Biotechnology Inc 61
Vicore Pharma AB 62
Yuhan Corp 62
Idiopathic Pulmonary Fibrosis - Drug Profiles 63
AB-22 - Drug Profile 63
acALY-18 - Drug Profile 64
AD-114 - Drug Profile 65
AEOL-10150 - Drug Profile 67
AF-102 - Drug Profile 77
AIK-3b - Drug Profile 78
Antisense RNAi Oligonucleotide for Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis - Drug Profile 79
Antisense RNAi Oligonucleotide to Inhibit HSP47 for Idiopathic Pulmonary Fibrosis - Drug Profile 80
APL-1 - Drug Profile 81
ATYR-1923 - Drug Profile 82
BG-00011 - Drug Profile 83
BLR-500 - Drug Profile 84
BMS-986020 - Drug Profile 85
C-21 - Drug Profile 86
CC-90001 - Drug Profile 89
CDX-0158 - Drug Profile 90
CG-1011 - Drug Profile 93
CGEN-25009 - Drug Profile 94
CM-101 - Drug Profile 95
CT-365 - Drug Profile 96
CWHM-12 - Drug Profile 97
D-9030 - Drug Profile 98
FSMAB-26 - Drug Profile 99
FST-12 - Drug Profile 100
GBT-1118 - Drug Profile 101
GBT-440 - Drug Profile 102
gefapixant - Drug Profile 108
GKT-831 - Drug Profile 112
GLPG-1690 - Drug Profile 115
GLPG-2938 - Drug Profile 117
GRC-388XX - Drug Profile 118
Grx1-iSPERSE - Drug Profile 119
GSK-3008348 - Drug Profile 120
HEC-585 - Drug Profile 121
HR-017 - Drug Profile 122
IBIOCFB-03 - Drug Profile 123
ICG-001 - Drug Profile 125
IGP-002 - Drug Profile 126
ISTH-0047 - Drug Profile 127
IVA-337 - Drug Profile 129
KAR-5585 - Drug Profile 131
KBP-7018 - Drug Profile 132
KD-025 - Drug Profile 133
lebrikizumab - Drug Profile 138
LT-1001 - Drug Profile 142
LTI-03 - Drug Profile 143
MMI-0100 - Drug Profile 144
Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis - Drug Profile 146
MOR-107 - Drug Profile 147
MRG-201 - Drug Profile 148
NAS-911 - Drug Profile 150
Neumomir - Drug Profile 152
NUE-7770 - Drug Profile 153
OATD-01 - Drug Profile 154
OLX-101 - Drug Profile 156
OLX-201 - Drug Profile 158
omipalisib - Drug Profile 159
P-013 - Drug Profile 160
pamrevlumab - Drug Profile 161
PBF-1129 - Drug Profile 168
PBI-4050 - Drug Profile 169
pirfenidone - Drug Profile 176
pirfenidone - Drug Profile 178
PRI-724 - Drug Profile 179
PRM-151 - Drug Profile 181
PUR-1500 - Drug Profile 186
PXS-4820 - Drug Profile 187
RBM-005 - Drug Profile 188
RBM-006 - Drug Profile 189
Refacell-IPF - Drug Profile 190
RP-0217 - Drug Profile 191
RT-1840 - Drug Profile 192
RT-234 - Drug Profile 193
SAR-156597 - Drug Profile 194
SM-04646 - Drug Profile 195
Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile 196
Small Molecules for COPD and IPF - Drug Profile 197
Small Molecules for Idiopathic Pulmonary Fibrosis - Drug Profile 198
Small Molecules for Idiopathic Pulmonary Fibrosis - Drug Profile 199
Small Molecules for Idiopathic Pulmonary Fibrosis - Drug Profile 200
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 201
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 202
Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile 203
Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer - Drug Profile 204
Small Molecules to Inhibit CHIT-1 for IPF and COPD - Drug Profile 205
Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile 206
Small Molecules to Inhibit MRTF and SRF for Idiopathic Pulmonary Fibrosis - Drug Profile 207
Small Molecules to Inhibit Porcupine for Immunology, Respiratory, Gastrointestinal and Metabolic Disorders - Drug Profile 208
Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile 209
SPL-334 - Drug Profile 210
SPL-334.1 - Drug Profile 211
SPL-891.1 - Drug Profile 212
Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile 213
Stem Cell Therapy for Idiopathic Lung Fibrosis and Asthma - Drug Profile 214
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile 215
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile 216
Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 217
TD-139 - Drug Profile 218
thrombomodulin alfa - Drug Profile 219
tipelukast - Drug Profile 221
vismodegib - Drug Profile 226
Wnt-001 - Drug Profile 232
YH-siRNA1 - Drug Profile 233
ZL-2102 - Drug Profile 234
Idiopathic Pulmonary Fibrosis - Dormant Projects 235
Idiopathic Pulmonary Fibrosis - Discontinued Products 238
Idiopathic Pulmonary Fibrosis - Product Development Milestones 239
Featured News & Press Releases 239
Appendix 246
Methodology 246
Coverage 246
Secondary Research 246
Primary Research 246
Expert Panel Validation 246
Contact Us 246
Disclaimer 247

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Allinky Biopharma, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by aTyr Pharma Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by BLR Bio LLC, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Celldex Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by GNI Group Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Histocell SL, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Merck & Co Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by miRagen Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Promedior Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Re-Pharm Ltd, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Redx Pharma Plc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma LLC, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Unity Biotechnology Inc, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H1 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corp, H1 2017
Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2017
Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2017